Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Federico Perno

Showing results (1-10 of 478) with videos related to

Pageof 48
Sort By:
Annali Dell'Istituto Superiore Di Sanita|March 25, 2011
The discovery and development of HIV therapy: the new challengesCarlo Federico Perno
Methods in Molecular Biology (Clifton, N.J.)|August 3, 2005
Assessing the relative efficacy of antiretroviral activity of different drugs on macrophagesStefano Aquaro, Carlo-Federico Perno
Journal of Global Antimicrobial Resistance|August 26, 2019
Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safetyValeria Cento, Carlo Federico Perno
Diagnostics (Basel, Switzerland)|May 5, 2021
Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 EraValeria Cento, Carlo Federico Perno
ISRN Microbiology|July 12, 2013
HIV-1 Genetic Variability and Clinical ImplicationsMaria Mercedes Santoro, Carlo Federico Perno
Current Opinion in Infectious Diseases|November 19, 2003
Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testingAndrea De Luca, Carlo-Federico Perno
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 1, 2017
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panelMauro Viganò, Carlo Federico Perno, Antonio Craxì, et al.
Current Opinion in HIV and AIDS|August 7, 2015
Resistance to direct-acting antiviral agents: clinical utility and significanceValeria Cento, Stephane Chevaliez, Carlo Federico Perno
The New Microbiologica|July 5, 2017
Biotech innovations in the prevention of respiratory infectious diseasesJulia Valeria Cento, Silvia Barbaliscia, Carlo Federico Perno
AIDS Reviews|January 16, 2007
Novel drug resistance mutations in HIV: recognition and clinical relevanceCarlo Federico Perno, Valentina Svicher, Francesca Ceccherini-Silberstein
Pageof 48

Showing results (1-10 of 478) with videos related to

Sort By:
Pageof 48
Annali Dell'Istituto Superiore Di Sanita|March 25, 2011
The discovery and development of HIV therapy: the new challengesCarlo Federico Perno
Methods in Molecular Biology (Clifton, N.J.)|August 3, 2005
Assessing the relative efficacy of antiretroviral activity of different drugs on macrophagesStefano Aquaro, Carlo-Federico Perno
Journal of Global Antimicrobial Resistance|August 26, 2019
Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safetyValeria Cento, Carlo Federico Perno
Diagnostics (Basel, Switzerland)|May 5, 2021
Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 EraValeria Cento, Carlo Federico Perno
ISRN Microbiology|July 12, 2013
HIV-1 Genetic Variability and Clinical ImplicationsMaria Mercedes Santoro, Carlo Federico Perno
Current Opinion in Infectious Diseases|November 19, 2003
Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testingAndrea De Luca, Carlo-Federico Perno
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 1, 2017
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panelMauro Viganò, Carlo Federico Perno, Antonio Craxì, et al.
Current Opinion in HIV and AIDS|August 7, 2015
Resistance to direct-acting antiviral agents: clinical utility and significanceValeria Cento, Stephane Chevaliez, Carlo Federico Perno
The New Microbiologica|July 5, 2017
Biotech innovations in the prevention of respiratory infectious diseasesJulia Valeria Cento, Silvia Barbaliscia, Carlo Federico Perno
AIDS Reviews|January 16, 2007
Novel drug resistance mutations in HIV: recognition and clinical relevanceCarlo Federico Perno, Valentina Svicher, Francesca Ceccherini-Silberstein
Pageof 48